Single intracoronary injection of encapsulated antagomir-92a promotes angiogenesis and prevents adverse infarct remodeling

Neus Bellera, Ignasi Barba, Antonio Rodriguez-Sinovas, Eulalia Ferret, Miguel Angel Asín, Ma Teresa Gonzalez-Alujas, Jordi Pérez-Rodon, Marielle Esteves, Carla Fonseca, Nuria Toran, Bruno Garcia del Blanco, Amadeo Pérez, David Garcia-Dorado

Research output: Contribution to journalArticleResearchpeer-review

34 Citations (Scopus)

Abstract

© 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. Background-Small and large preclinical animal models have shown that antagomir-92a-based therapy reduces early postischemic loss of function, but its effect on postinfarction remodeling is not known. In addition, the reported remote miR-92a inhibition in noncardiac organs prevents the translation of nonvectorized miR-targeted therapy to the clinical setting. We investigated whether a single intracoronary administration of antagomir-92a encapsulated in microspheres could prevent deleterious remodeling of myocardium 1 month after acute myocardial infarction AUTHOR: Should "acute" be added before "myocardial infarction" (since abbreviation is AMI)? Also check at first mention in main text (AMI) without adverse effects. Methods and Results-In a percutaneous pig model of reperfused AMI, a single intracoronary administration of antagomir-92a encapsulated in specific microspheres (9 μm poly-D,-lactide-co-glycolide [PLGA]) inhibited miR-92a in a local, selective, and sustained manner (n=3 pigs euthanized 1, 3, and 10 days after treatment; 8×, 2×, and 5×-fold inhibition at 1, 3, and 10 days). Downregulation of miR-92a resulted in significant vessel growth (n=27 adult minipigs randomly allocated to blind receive encapsulated antagomir-92a, encapsulated placebo, or saline [n=8, 9, 9]; P=0.001), reduced regional wall-motion dysfunction (P=0.03), and prevented adverse remodeling in the infarct area 1 month after injury (P=0.03). Intracoronary injection of microspheres had no significant adverse effect in downstream myocardium in healthy pigs (n=2), and fluorescein isothiocyanate albumin-PLGA microspheres were not found in myocardium outside the left anterior descending coronary artery territory (n=4) or in other organs (n=2). Conclusions-Early single intracoronary administration of encapsulated antagomir-92a in an adult pig model of reperfused AMI prevents left ventricular remodeling with no local or distant adverse effects, emerging as a promising therapeutic approach to translate to patients who suffer a large AMI.
Original languageEnglish
Article numbere000946
JournalJournal of the American Heart Association
Volume3
Issue number5
DOIs
Publication statusPublished - 1 Jan 2014

Keywords

  • Angiogenesis
  • Antagomir
  • Heart failure
  • MicroRNA
  • Myocardial infarction
  • Remodeling

Fingerprint Dive into the research topics of 'Single intracoronary injection of encapsulated antagomir-92a promotes angiogenesis and prevents adverse infarct remodeling'. Together they form a unique fingerprint.

Cite this